JAQBO Trademark

Trademark Overview


On Thursday, September 14, 2023, a trademark application was filed for JAQBO with the United States Patent and Trademark Office. The USPTO has given the JAQBO trademark a serial number of 79383436. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, September 3, 2024. This trademark is owned by JEIL PHARMACEUTICAL CO., LTD. The JAQBO trademark is filed in the Pharmaceutical Products category with the following description:

Veterinary pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitor, namely, medicines for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infe...
jaqbo

General Information


Serial Number79383436
Word MarkJAQBO
Filing DateThursday, September 14, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateTuesday, September 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 8, 2024

Trademark Statements


Goods and ServicesVeterinary pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitor, namely, medicines for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; medicines for the prevention and treatment of gastrointestinal diseases; medicines for the treatment of gastrointestinal diseases; medicines for human purposes, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; ethical medicinal preparations, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 20, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameJEIL PHARMACEUTICAL CO., LTD
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Thursday, May 9, 2024NON-FINAL ACTION WRITTEN
Thursday, November 16, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, November 20, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 24, 2023APPLICATION FILING RECEIPT MAILED
Thursday, May 9, 2024ASSIGNED TO EXAMINER
Friday, May 10, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 10, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, June 11, 2024REFUSAL PROCESSED BY IB
Tuesday, July 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 30, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 3, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, September 3, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, September 3, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, September 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 3, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, September 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED